Modulation of Th1/Th2 balance by infliximab rescues postoperative occurrence of small-intestinal inflammation associated with ulcerative colitis

Dig Dis Sci. 2010 Jun;55(6):1781-4. doi: 10.1007/s10620-009-0910-5. Epub 2009 Aug 12.

Authors

Reiko Akitake¹, Hiroshi Nakase, Masashi Tamaoki, Satoru Ueno, Sakae Mikami, Tsutomu Chiba

Affiliation

¹ Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto, Japan.

PMID: 19672713
DOI: 10.1007/s10620-009-0910-5

No abstract available

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Anti-Inflammatory Agents / therapeutic use*
Antibodies, Monoclonal / therapeutic use*
Biopsy
Colitis, Ulcerative / diagnosis
Colitis, Ulcerative / drug therapy*
Colitis, Ulcerative / immunology
Colonic Pouches / adverse effects
Digestive System Surgical Procedures / adverse effects*
Duodenitis / diagnosis
Duodenitis / drug therapy*
Duodenitis / immunology
Duodenum / drug effects*
Duodenum / immunology
Endoscopy, Digestive System
Female
Gastrointestinal Agents / therapeutic use*
Humans
Ileostomy / adverse effects
Infliximab
Pouchitis / drug therapy
Pouchitis / immunology
Proctocolectomy, Restorative / adverse effects
Recurrence
Th1 Cells / drug effects*
Th1 Cells / immunology
Th2 Cells / drug effects*
Th2 Cells / immunology
Tomography, X-Ray Computed
Treatment Outcome

Substances

Anti-Inflammatory Agents
Antibodies, Monoclonal
Gastrointestinal Agents
Infliximab